Please login to the form below

Not currently logged in
Email:
Password:

Ilaris

This page shows the latest Ilaris news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EULAR kicks off in Amsterdam, May brings together remainers and brexiteers and Autolus launches its IPOS

Daily Brief: EULAR kicks off in Amsterdam, May brings together remainers and brexiteers and Autolus launches its IPOS

On today’s agenda expect new trial data from Novartis' Ilaris in gout, Lilly's Oluminant in systemic lupus and AbbVie's new JAK inhibitor upadacitinib.

Latest news

  • CV data sets up Novartis' Ilaris for blockbuster sales CV data sets up Novartis' Ilaris for blockbuster sales

    CV data sets up Novartis' Ilaris for blockbuster sales. Drug shown to reduce major adverse cardiovascular events. ... Novartis has posted surprise phase III data that could transform the fortunes of its anti-inflammatory drug Ilaris, making it an option

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    Novartis' Ilaris wins three new FDA approvals. Immunotherapeutic expands in rare Periodic Fever Syndrome conditions. ... Novartis' anti-inflammatory therapy Ilaris (canakinumab) has received new US approvals for its use in three rare Periodic Fever

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... Novartis' inflammatory disease drug Ilaris (canakinumab) can be used more widely in the EU

  • Novartis lifts 2013 guidance on delay to Diovan generics Novartis lifts 2013 guidance on delay to Diovan generics

    Jimenez also said Novartis had a fertile quarter in terms of its pipeline, with four approvals including Ilaris (canakinumab) for systemic juvenile idiopathic arthritis, Simbrinza (brinzolamide/brimonidine tartrate) for glaucoma, Lucentis

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... The new SJIA indication will add further momentum to Ilaris, which grew 56 per cent last year to reach $72m in sales.

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics